0.9931
Medicus Pharma Ltd 주식(MDCX)의 최신 뉴스
Medicus Pharma cleared to launch Phase 2b Teverelix study in Prostate Cancer - Proactive financial news
Medicus Pharma Partners With Gorlin Syndrome Alliance to Expand Access to SKINJECT - MSN
Medicus Pharma on Bloomberg World - Weatherford Democrat
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - PhillyBurbs
FDA clears Medicus Pharma’s prostate cancer drug for phase 2b trial By Investing.com - Investing.com South Africa
FDA clears Medicus Pharma’s prostate cancer drug for phase 2b trial - Investing.com Nigeria
New to The Street Signs Six-Part Media Series Featuring Medicus Pharma Ltd. - USA Today
Small cap wrap: Medicus Pharma, 1911 Gold, NanoViricides, Nextech3D.ai, NextSource Materials… - Proactive financial news
Medicus Pharma Wins FDA Go-Ahead for Phase 2b Teverelix Trial in High-Risk Prostate Cancer - TipRanks
Medicus Pharma receives FDA clearance to proceed with Phase 2b prostate cancer study - Proactive financial news
Medicus Pharma Receives FDA 'Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk - The Manila Times
FDA clears trial of Teverelix for prostate cancer with high heart risk - Stock Titan
How Medicus Pharma Ltd. Equity Warrant stock reacts to inflationary pressures2025 Support & Resistance & Momentum Based Trading Ideas - mfd.ru
Trade Report: Can Medicus Pharma Ltd expand its profit marginsJuly 2025 Review & Risk Managed Trade Strategies - baoquankhu1.vn
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform - The Marion Star
Merger Talk: Can Medicus Pharma Ltd expand its profit marginsTrade Entry Summary & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Medicus Pharma Reports Q3 Loss Amid Strategic Growth - MSN
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement - Canton Repository
자본화:
|
볼륨(24시간):